Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Telesis Bio Inc. (TBIO) generates news centered on automated DNA and mRNA synthesis technologies, strategic collaborations and corporate developments. The company describes itself as a public company based in San Diego, California, focused on enabling scientists to produce high-fidelity DNA and mRNA directly in their own laboratories using its Gibson SOLA Enzymatic Synthesis platform and BioXp benchtop systems.
News coverage for Telesis Bio often highlights progress and adoption of the Gibson SOLA™ platform, which the company presents as a non-toxic, high-fidelity and scalable enzymatic DNA and mRNA synthesis technology. Announcements have included licensing agreements, such as the deployment of Gibson SOLA at Regeneron Pharmaceuticals’ R&D core facilities, and collaborations that integrate Gibson SOLA with third-party automation platforms to support on-premises biofoundry capabilities.
Investors and researchers following TBIO can expect updates on partnerships and collaborations, including the company’s strategic research collaboration and license agreement with Pfizer related to enzymatic DNA synthesis for potential mRNA-based vaccines and other biopharma products. Additional news may cover agreements with automation and life sciences companies to co-develop and market integrated solutions for high-throughput nucleic acid synthesis.
Corporate and capital markets developments also appear in Telesis Bio’s news flow. Examples include restructuring activities, strategic focus on Gibson SOLA and BioXp mRNA solutions, reverse stock split actions, and the company’s decision to voluntarily delist from The Nasdaq Global Select Market and pursue quotation on over-the-counter markets. For anyone tracking TBIO, the news stream provides context on how the company is positioning its synthesis platforms, managing its cost structure and engaging with partners in synthetic biology and drug discovery workflows.
Translate Bio (NASDAQ: TBIO) announced the granting of non-qualified stock options for 111,800 shares to 14 newly hired employees as part of its 2021 Inducement Stock Incentive Plan. The options have an exercise price of $16.82, equal to the stock's closing price on April 5, 2021. These options vest over four years, with 25% vesting on April 5, 2022. This initiative aims to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4). Translate Bio focuses on developing mRNA therapeutics to treat pulmonary diseases and collaborate on mRNA vaccines for infectious diseases.
Translate Bio (Nasdaq: TBIO) announced the granting of non-qualified stock options for 300,000 shares to its new President, Dr. Rand Sutherland, on March 22, 2021. The exercise price is set at $16.37 per share, corresponding to the closing price on that date. The options have a ten-year term, vesting over four years with specific conditions for early vesting. This grant is part of the company's 2021 Inducement Stock Incentive Plan and aims to incentivize Dr. Sutherland's employment.
Translate Bio (Nasdaq: TBIO) announced the appointment of Dr. Rand Sutherland as President, effective March 22, 2021. With 20 years of experience in the medical and industry sectors focusing on pulmonary and rare diseases, Dr. Sutherland previously led Global Medical Affairs at Sanofi Genzyme. In his new role, he will oversee research, development, and corporate strategy to enhance the company’s mRNA therapeutic pipeline. CEO Ronald Renaud emphasized Dr. Sutherland's critical role in advancing the company’s innovative mRNA medicines, targeting genetic diseases, and improving patient care.
Translate Bio has reported promising interim results from its Phase 1/2 clinical trial of MRT5005, designed to treat cystic fibrosis (CF) by delivering mRNA encoding CFTR protein to the lungs. The trial showed that multiple doses of MRT5005 were generally safe and well tolerated with no serious adverse events. However, there was no observed pattern of increase in lung function, measured by percent predicted forced expiratory volume in 1 second (ppFEV1). The company plans further research to optimize the therapeutic approach and advance its next-generation CF candidate.
Translate Bio and Sanofi Pasteur have initiated a Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate targeting SARS-CoV-2. The trial aims to enroll 415 participants and evaluate safety, immune response, and tolerability. Interim results are expected in Q3 2021. Upon trial initiation, Translate Bio will receive a $25 million payment. Preclinical data indicated high neutralizing antibody levels, with ongoing studies assessing responses to emerging variants. The collaboration reflects significant progress in mRNA vaccine development for infectious diseases.
On March 1, 2021, Translate Bio (Nasdaq: TBIO) announced the grant of non-qualified stock options for 54,250 shares to seven new employees. This move, part of the 2021 Inducement Stock Incentive Plan, is intended to incentivize staff acceptance of employment. The options carry an exercise price of $23.80 per share, matching the closing stock price on the same day, with a vesting schedule over four years. Translate Bio focuses on mRNA therapeutics, particularly in treating pulmonary diseases and developing mRNA vaccines through a collaboration with Sanofi Pasteur.
Translate Bio (Nasdaq: TBIO) reported its fourth quarter and full year 2020 results, showcasing significant developments in its mRNA therapeutics pipeline. The company expects interim data from the Phase 1/2 trial of MRT5005 for cystic fibrosis in early Q2 2021 and plans to initiate two infectious disease vaccine programs, including COVID-19 and influenza, in collaboration with Sanofi Pasteur. Despite a net loss of $20.6 million in Q4 2020, collaboration revenue rose to $51.4 million, driven by increased vaccine activities. With $654 million in cash, the firm believes it can sustain operations through 2023.
Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, announced CEO Ronald Renaud's participation in a fireside chat at the SVB Leerink Virtual 10th Annual Global Healthcare Conference on February 26, 2021, at 9:20 a.m. EST. This event highlights the company's focus on transformative mRNA medicines aimed at treating life-threatening diseases, particularly pulmonary diseases like cystic fibrosis. Interested parties can access the live webcast via the company's website, with archived replays available for 30 days.
Translate Bio (Nasdaq: TBIO) announced on February 1, 2021, the grant of non-qualified stock options to purchase 57,550 shares to four new employees. These options, part of the 2021 Inducement Stock Incentive Plan, have an exercise price of $24.46 per share and a ten-year term, vesting over four years. The Company's lead candidate aims to treat cystic fibrosis and is currently in a Phase 1/2 clinical trial. Translate Bio is also developing mRNA vaccines for infectious diseases in collaboration with Sanofi Pasteur.
Translate Bio (NASDAQ: TBIO) has completed enrollment and dosing for its Phase 1/2 clinical trial of MRT5005, the first mRNA therapeutic administered via nebulization for cystic fibrosis. This trial includes 8, 12, and 16 mg multiple-ascending dose groups, alongside a 20 mg single-ascending dose group. Interim clinical data is expected early in Q2 2021. MRT5005 aims to treat all CF patients regardless of genetic mutation, addressing a significant unmet need. The FDA has granted MRT5005 several designations, including Orphan Drug and Fast Track.